Literature DB >> 15288011

Plasma osteopontin levels in patients with fulminant hepatitis.

Atsushi Matsui1, Satoshi Mochida, Akihiko Ohno, Sumiko Nagoshi, Takanori Hirose, Kenji Fujiwara.   

Abstract

Fulminant hepatitis is characterized by massive or submassive liver necrosis. Massive liver necrosis can be induced by activated macrophages infiltrating into the liver. Osteopontin, an extracellular matrix, is a secretory glycoprotein as well essential for Th1 immune response, contributing to macrophage activation and infiltration. To know the significance of osteopontin in the development of fulminant hepatitis, plasma osteopontin levels were measured in patients with fulminant hepatitis. The levels were significantly greater in patients with fulminant hepatitis than in those with acute or chronic hepatitis as well as healthy adults. Among patients with fulminant hepatitis except one in whom bacterial infection was complicated, plasma osteopontin levels were elevated especially in the patients who developed hepatic encephalopathy of grade II or more within 10 days of the disease onset, a clinical type characteristic of massive liver necrosis. Immunohistochemical examination revealed that osteopontin was stained in macrophages positive for CD68, a marker for macrophages, in necrotic areas of the liver in a patient with fulminant hepatitis. In conclusion, plasma osteopontin levels were elevated in patients with fulminant hepatitis, probably reflecting production of osteopontin in Kupffer cells and hepatic macrophages, which might be involved in the development of massive liver necrosis in fulminant hepatitis.

Entities:  

Year:  2004        PMID: 15288011     DOI: 10.1016/j.hepres.2004.03.009

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  17 in total

1.  Association of circulating osteopontin levels with clinical outcomes in postoperative biliary atresia.

Authors:  Sittisak Honsawek; Paisarn Vejchapipat; Voranush Chongsrisawat; Nutchanart Thawornsuk; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2010-11-03       Impact factor: 1.827

2.  Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations.

Authors:  Iman H Bassyouni; Rasha H Bassyouni; Nermin H Ibrahim; Ahmed F Soliman
Journal:  J Clin Immunol       Date:  2012-06-24       Impact factor: 8.317

3.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.

Authors:  Hui Zhang; Qing-Hai Ye; Ning Ren; Lei Zhao; Yan-Fang Wang; Xin Wu; Hui-Chuan Sun; Lu Wang; Bo-Heng Zhang; Yin-Kun Liu; Zhao-You Tang; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

4.  Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure.

Authors:  Kazuhiro Kotoh; Masaki Kato; Motoyuki Kohjima; Masatake Tanaka; Masayuki Miyazaki; Kazuhiko Nakamura; Munechika Enjoji; Makoto Nakamuta; Ryoichi Takayanagi
Journal:  Exp Ther Med       Date:  2011-01-19       Impact factor: 2.447

5.  A new treatment strategy for acute liver failure.

Authors:  Kazuhiro Kotoh; Masaki Kato; Motoyuki Kohjima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Hepatol       Date:  2010-11-27

6.  Increased osteopontin and liver stiffness measurement by transient elastography in biliary atresia.

Authors:  Sittisak Honsawek; Maneerat Chayanupatkul; Voranush Chongsrisawat; Paisarn Vejchapipat; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

7.  Plasma osteopontin in acute liver failure.

Authors:  Praveen Srungaram; Jody A Rule; He Jun Yuan; Andreas Reimold; Benny Dahl; Corron Sanders; William M Lee
Journal:  Cytokine       Date:  2015-03-21       Impact factor: 3.861

8.  Acute liver failure caused by drug-induced hypersensitivity syndrome associated with hyperferritinemia.

Authors:  Masayuki Miyazaki; Masatake Tanaka; Akihiro Ueda; Tsuyoshi Yoshimoto; Masaki Kato; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

9.  Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure.

Authors:  Kazuhiro Kotoh; Munechika Enjoji; Makoto Nakamuta; Tsuyoshi Yoshimoto; Motoyuki Kohjima; Shusuke Morizono; Shinsaku Yamashita; Yuki Horikawa; Kengo Yoshimitsu; Tsuyoshi Tajima; Yoshiki Asayama; Kousei Ishigami; Masakazu Hirakawa
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

10.  Antithrombin III injection via the portal vein suppresses liver damage.

Authors:  Masayuki Miyazaki; Masaki Kato; Masatake Tanaka; Kosuke Tanaka; Shinichiro Takao; Motoyuki Kohjima; Tetsuhide Ito; Munechika Enjoji; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.